Drug Trial Radar · NCT07109297
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Actual
Start
Jul 31, 2025
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 months, up to 24 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Conditions
- RSV Immunization
Interventions
NirsevimabBiological
Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of immediate adverse events (AEs)Time frame: Within 30 minutes after immunization
- Presence of non-serious AEsTime frame: From Day 01 through Day 31
- Presence of adverse events of special interest (AESIs) throughout the studyTime frame: Throughout the study (approximately 6 months)
- Presence of medically attended adverse events (MAAEs) throughout the studyTime frame: Throughout the study (approximately 6 months)
- Presence of serious adverse events (SAEs) throughout the studyTime frame: Throughout the study (approximately 6 months)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 3560002
Bengaluru, India
Investigational Site Number : 3560008
Jaipur, India
Investigational Site Number : 3560003
Kolkata, India
Investigational Site Number : 3560007
Nagpur, India
Investigational Site Number : 3560001
New Delhi, India
Investigational Site Number : 3560004
Pune, India
Investigational Site Number : 3560006
Vizianagaram, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.